Objective:To analyze the efficacy of the combination therapy of pembrolizumab,a programmed death receptor-1(PD-1)inhibitor,and chemotherapy in the treatment of cervical cancer.Methods:A total of 60 patients with cervical cancer who visited our hospital from January 2020 to January 2023 were selected and divided into two groups:30 patients were treated with first-line chemotherapy,and 30 patients were treated with pembrolizumab combined with first-line chemotherapy.Compare the recent efficacy of two groups,including immune related indicators[CD4+/CD8+ratio,interleukin-6(IL-6),interferon-γ(IFN-γ)],serum tumor markers[Squamous Cell Carcinoma Antigen(SCC Ag),Carbohydrate Antigen 125(CA125)],incidence of adverse reactions,and survival status[Progression Free Survival(PFS),Overall Survival(OS)]before and after treatment.Results:The objective response rate(ORR)of the combination group was 73.33％,while that of the chemotherapy group was 40.00％.The combination group was higher than the chemotherapy group(P＜0.05);There was no significant difference in the levels of CD4+/CD8+,IL-6,and IFN-γ between the two groups before treatment(P＞0.05).After treatment,the levels of CD4+/CD8+,IL-6,and IFN-γ decreased in the combination group,which was lower than those in the chemotherapy group(P＜0.05);There was no significant difference in the levels of SCC Ag and CA125 between the two groups before treatment(P＞0.05).After treatment,the levels of SCC Ag and CA125 in both groups decreased,with the combination group lower than the chemotherapy group(P＜0.05);There was no significant difference in the incidence of hematological toxicity(anemia,thrombocytopenia),immune related toxicity(hypothyroidism,immune pneumonia,elevated transaminase),skin/mucosal reactions(rash,oral mucosal inflammation),and other adverse reactions(diarrhea,fatigue)between the two groups(P＞0.05).The incidence of grade 3 or above neutropenia was higher in the chemotherapy group than in the combination group(P＜0.05);The PFS and OS time of the combined group were higher than those of the chemotherapy group(P＜0.05).Conclusion:The combination therapy of PD-1 inhibitor pembrolizumab and chemotherapy is significantly effective in treating cervical cancer,which can improve the immune environment,reduce serum marker levels,and has high safety.At the same time,through long-term follow-up,it was found that the combination therapy can further improve patients'long-term progression free survival and overall survival.

Objective:To analyze the efficacy of the combination therapy of pembrolizumab,a programmed death receptor-1(PD-1)inhibitor,and chemotherapy in the treatment of cervical cancer.Methods:A total of 60 patients with cervical cancer who visited our hospital from January 2020 to January 2023 were selected and divided into two groups:30 patients were treated with first-line chemotherapy,and 30 patients were treated with pembrolizumab combined with first-line chemotherapy.Compare the recent efficacy of two groups,including immune related indicators[CD4+/CD8+ratio,interleukin-6(IL-6),interferon-γ(IFN-γ)],serum tumor markers[Squamous Cell Carcinoma Antigen(SCC Ag),Carbohydrate Antigen 125(CA125)],incidence of adverse reactions,and survival status[Progression Free Survival(PFS),Overall Survival(OS)]before and after treatment.Results:The objective response rate(ORR)of the combination group was 73.33％,while that of the chemotherapy group was 40.00％.The combination group was higher than the chemotherapy group(P＜0.05);There was no significant difference in the levels of CD4+/CD8+,IL-6,and IFN-γ between the two groups before treatment(P＞0.05).After treatment,the levels of CD4+/CD8+,IL-6,and IFN-γ decreased in the combination group,which was lower than those in the chemotherapy group(P＜0.05);There was no significant difference in the levels of SCC Ag and CA125 between the two groups before treatment(P＞0.05).After treatment,the levels of SCC Ag and CA125 in both groups decreased,with the combination group lower than the chemotherapy group(P＜0.05);There was no significant difference in the incidence of hematological toxicity(anemia,thrombocytopenia),immune related toxicity(hypothyroidism,immune pneumonia,elevated transaminase),skin/mucosal reactions(rash,oral mucosal inflammation),and other adverse reactions(diarrhea,fatigue)between the two groups(P＞0.05).The incidence of grade 3 or above neutropenia was higher in the chemotherapy group than in the combination group(P＜0.05);The PFS and OS time of the combined group were higher than those of the chemotherapy group(P＜0.05).Conclusion:The combination therapy of PD-1 inhibitor pembrolizumab and chemotherapy is significantly effective in treating cervical cancer,which can improve the immune environment,reduce serum marker levels,and has high safety.At the same time,through long-term follow-up,it was found that the combination therapy can further improve patients'long-term progression free survival and overall survival.